Search Results - Suzanne MacRae
- Showing 1 - 3 results of 3
-
1
Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma by F. Stephen Hodi, Philip Friedlander, Christopher L. Corless, Michael C. Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi P. Jagannathan, Annick D. Van den Abbeele, Elsa F. Velázquez, George D. Demetri, David E. Fisher
Published 2008Artigo -
2
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients by F. Stephen Hodi, Martín C. Mihm, Robert J. Soiffer, Frank G. Haluska, Marcus O. Butler, Michael V. Seiden, Thomas A. Davis, Rochele Henry-Spires, Suzanne MacRae, Ann Willman, Robert F. Padera, Michael T. Jaklitsch, Sridhar Shankar, Teresa C. Chen, Alan J. Korman, James P. Allison, Glenn Dranoff
Published 2003Artigo -
3
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients by F. Stephen Hodi, Marcus O. Butler, Darryl A. Oble, Michael V. Seiden, Frank G. Haluska, Andrea Kruse, Suzanne MacRae, Marybeth Nelson, Christine Canning, Israel Lowy, Alan J. Korman, David B. Lautz, Sara E. Russell, Michael T. Jaklitsch, Nikhil H. Ramaiya, Teresa C. Chen, Donna Neuberg, James P. Allison, Martín C. Mihm, Glenn Dranoff
Published 2008Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Antibody
Antigen
Biochemistry
Biology
Blocking antibody
Cancer
Cancer research
Cytotoxic T cell
Immune system
Immunology
Immunotherapy
In vitro
Melanoma
Cancer immunotherapy
Chemistry
Environmental health
FOXP3
Imatinib
Imatinib mesylate
Immunogenicity
Ipilimumab
Mesylate
Myeloid leukemia
Oncology
Organic chemistry
Pharmacology
Population
Tumor antigen